Pharmacogenetics of opioids: a narrative review

Kumar, Shathish; Kundra, Pankaj; Ramsamy, K.; Chandrasekaran, Adithan

doi:10.1111/anae.14813

Cited by 29 publications

(25 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it is important to note that there are many reasons, both genetic and other, that underlie the significant interindividual variability in opioid sensitivity. Therefore, regardless of CYP2D6 status, it is prudent that all patients be required to demonstrate tolerability to any opioid that they will receive on discharge 29 …”

Section: Discussionmentioning

confidence: 99%

Impact of a revised postoperative care plan on pain and recovery trajectory following pediatric tonsillectomy

Lagrange

Jepp

Slevin

et al. 2021

Pediatric Anesthesia

View full text Add to dashboard Cite

Background A previous cohort of adenotonsillectomy patients at our institution demonstrated moderate‐severe post‐tonsillectomy pain scores lasting a median (range) duration of 6 (0–23) days and postdischarge nausea and vomiting affecting 8% of children on day 1 following surgery. In this subsequent cohort, we evaluate the impact of changes to our discharge medication and parental education on post‐tonsillectomy pain and recovery profile. Methods In this follow‐on, prospective observational cohort study, all patients undergoing tonsillectomy at our institution during the study period were discharged with standardized analgesia. Parents received a revised education package and a medication diary which were not provided to the previous cohort. Pain scores, rates of nausea and vomiting, medication usage and unplanned representation rates were collected by telephone from parents. Results Sixty‐nine patients were recruited. Moderate‐severe pain lasted a median (range) of 5 (0–12) days. Twenty‐nine (42%) had pain scores ≥4/10 beyond postoperative day 7. By postoperative day 5, only 37 (53%) parents continued to administer regular analgesia. The median number of oxycodone doses used was 5 (0–22), and only 28 (41%) parents had disposed of leftover oxycodone within 1 month of surgery. Twenty‐four (35%) patients experienced nausea or vomiting postdischarge. The median (range) time for return to normal activities was 6 (0–14) days. Thirty‐two/sixty‐nine (46%) patients had unplanned medical representations. Most occurred between postoperative day 5 and 7. Pain contributed to 16 (35%) representations. Conclusions Despite extensive changes to our discharge protocols parents continued to report a prolonged period of pain, post operative nausea and vomiting, and behavioral changes. Further work is required to examine barriers to compliance with simple analgesia and education in appropriate methods of opioid disposal.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of a revised postoperative care plan on pain and recovery trajectory following pediatric tonsillectomy

Lagrange

Jepp

Slevin

et al. 2021

Pediatric Anesthesia

View full text Add to dashboard Cite

show abstract

“…Часто реакция пациента на опиоидные анальгетики индивидуальна и трудно предсказуема, что затрудняет проведение обезболивания и поднимает вопрос о влиянии генетических факторов [17,29,30].…”

Section: использование фармакогенетического подхода в обезболиванииunclassified

Possibilities of Analgesia in Non-Cardiac Surgery: Personalized Approach

Sokolov¹,

Сироткина²,

Lyuboshevskiy³

2021

СПНО (MPSE)

View full text Add to dashboard Cite

“…According to some authors [ 58 ], if the subject is a poor metabolizer, inadequate analgesia can be observed. If CBD, THC, or CBN inhibition of CYP2D6 predominates, the analgesic effects of tramadol and codeine will be reduced.…”

Section: Drug-drug Interactionsmentioning

confidence: 99%

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain

Vázquez

Guevara

Maldonado

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Choosing an appropriate treatment for chronic pain remains problematic, and despite the available medication for its treatment, still, many patients complain about pain and appeal to the use of cannabis derivatives for pain control. However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications. Therefore, the aim of this brief review is to assess the interactions between cannabinoids and pain medication through drug transporters (ATP-binding cassette superfamily members) and/or metabolizing enzymes (cytochromes P450 and glucuronyl transferases).

show abstract

Pharmacogenetics of opioids: a narrative review

Cited by 29 publications

References 66 publications

Impact of a revised postoperative care plan on pain and recovery trajectory following pediatric tonsillectomy

Impact of a revised postoperative care plan on pain and recovery trajectory following pediatric tonsillectomy

Possibilities of Analgesia in Non-Cardiac Surgery: Personalized Approach

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain

Contact Info

Product

Resources

About